First experience with targeted therapy of lipid metabolism disorders in kidney transplant patients

Objective. To evaluate the efficacy and safety of the new drug inclisiran (Novartis Overseas investments, AG (/witzerland)) in patients with chronic kidney disease (CKD) and transplanted kidney with impaired lipid metabolism.

Material and methods. The first results of a prospective case series study in three patients with combined diseases: cardiovascular diseases (CVD), lipid metabolism disorder and CKD with transplanted kidney, who have a very high risk of cardiovascular complications are presented. All patients received maximum combined lipid-lowering therapy (statins and ezetimibe) and immunosuppressive therapy. With this therapy, the target level of low-density lipoproteins was not achieved.

Results. The patients underwent general clinical examination. Biochemical parameters, renal excretory function, immunosuppressive therapy, lipid metabolism parameters (total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides) were evaluated. The evaluation was carried out before the administration of inclisiran, 3 months after the first administration, six months after the second administration and before the third administration of inclisiran. At the study stages, a stable decrease by 18.4-19.1% in total cholesterol and 51-59.6% in low-density lipoproteins from baseline was found. The level of high-density lipoproteins and triglycerides did not change significantly. Correction of immunosuppressive therapy was not performed. No adverse events and complications were detected during the study. The target level of low-density lipoproteins was achieved.

Conclusion. The first data of the study on the use of inclisiran in patients with CVD, CKD with transplanted kidney and lipid metabolism disorders testify to its efficacy and safety.

1. Moysyuk YG, Sushkov AI. AB0-incompatible living donor kidney transplantation: the long-term outcomes. Almanac of Clinical Medicine. 2017;45(7):535–546. (In Russ.). https://doi.org/10.18786/2072-0505-2017-45-7-535-546

2. Gautier SV, Khomyakov SM, Strokov AG. Sovershenstvovanie organizatsii meditsinskoy pomoshchi po profilyu «Nefrologiya». Russian Journal of Transplantology and Artificial Organs. 2023;25(S):16–17. (In Russ.). URL: https://journal.transpl.ru/vtio/article/view/1695/1518

3. Andrusev AM, Peregudova NG, Shinkarev MB, Tomilina NA. Kidney replacement therapy for end Stage Kidney disease in Russian Federation, 2016-2020 Russian National Kidney Replacement Therapy. Registry Report of Russian Public Organization of Nephrologists “Russian Dialysis Society”. Nephrology and Dialysis. 2022;24(4):555–565. (In Russ.). https://doi.org/10.28996/2618-9801-2022-4-555-565

4. Khubutiya MSh, Dmitriev IV, Balkarov AG, Anisimov YuA, Shmarina NV, Zagorodnikova NV, et al. Single-center experience in kidney transplantation: outcomes, conclusions, and perspectives. Russian Journal of Transplantology and Artificial Organs. 2024;26(4):90–99. (In Russ.). https://doi.org/10.15825/1995-1191-2024-4-90-99

5. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S112–S119. PMID: 9820470 https://doi.org/10.1053/ajkd.1998.v32.pm9820470

6. Chukwu CA, Rao A, Middleton R, Kalra PA. Post-transplant cardiovascular disease in kidney transplant recipients: incidence, risk factors, and outcomes in the era of modern immunosuppression. J Clin Med. 2024;13(10):2734. PMID: 38792274 https://doi.org/10.3390/jcm13102734

7. Rangaswami J Mathew RO Parasuraman R, et al. Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. Nephrol Dial Transplant. 2019;34(5):760–773. PMID: 30984976 https://doi.org/10.1093/ndt/gfz053

8. Ezhov MV, Kukharchuk VV, Sergienko IV, Alieva AS, Antsiferov MB, Ansheles AA, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.). https://doi.org/10.15829/1560-4071-2023-5471

9. Nagel N, Rahamimov R, Bielopolski D, Steinmetz T, Skalsky K, Zingerman B, et al. Analysis of the correlation between hypercholesterolemia and increased cardiovascular morbidity and mortality among adult kidney transplant recipients. Kidney Blood Press Res. 2024;49(1):961–969. PMID: 39397635 https://doi.org/10.1159/000541910

10. Heleniak ZT, Illersperger S, Brakemeier S, Dębska-Ślizień A, Bach P, Budde K, et al. Influence of lipid profile and statin administration on arterial stiffness in renal transplant recipients. Cardiol J. 2022;29(2):263–271. PMID: 32329037 https://doi.org/10.5603/CJ.a2020.0063

11. Arabi Z, Tawhari M, Alghamdi AA, Alnasrullah A. Lipid management in kidney transplant recipients per KDIGO and American Heart Association Guidelines: a single-center experience. Saudi J Med Med Sci. 2024;12(1):47–53. PMID: 38362088 https://doi.org/10.4103/sjmms.sjmms_95_23

12. Heleniak ZT, Illersperger S, Brakemeier S, Dębska-Ślizień A, Bach P, Budde K, et al. Influence of lipid profile and statin administration on arterial stiffness in renal transplant recipients. Cardiol J. 2022;29(2):263–271. PMID: 32329037 https://doi.org/10.5603/CJ.a2020.0063

13. Thölking G, Schulte C, Jehn U, Schütte-Nütgen K, Pavenstädt H, Suwelack B, et al. The tacrolimus metabolism rate and dyslipidemia after kidney transplantation. J Clin Med. 2021;10(14):3066. PMID: 34300232 https://doi.org/10.3390/jcm10143066

14. Bae S, Ahn JB, Joseph C, Whisler R, Schnitzler MA, Lentine KL, et al. Statins in kidney transplant recipients: usage, all-cause mortality, and interactions with maintenance. J Am Soc Nephrol. 2023;34(6):1069–1077. PMID: 36890643 https://doi.org/10.1681/ASN.0000000000000112

15. Ueberdiek L, Jehn U, Pavenstädt H, Gebauer K, Reuter S. Novel therapeutic strategies for dyslipidemia: first report of inclisiran therapy in a kidney transplanted patient. Transpl Int. 2023;36:11104. PMID: 36776901 https://doi.org/10.3389/ti.2023.11104 eCollection 2023

16. Kordonova OO, Gubarev KK, Frolova NF, Svetlakova DS, Voskanyan SE, Artyukhina LYu. Treatment of dyslipidemia using inclisiran in a case series of patients after kidney and liver transplantation. Clinical Nephrology. 2024;16(2):13–23. (In Russ.). https://doi.org/10.18565/nephrology.2024.2.13-23

17. Wright RS, Collins MG, Stoekenbroek RM, Robson R, Wijngaard PLJ, Landmesser U, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies. Mayo Clin Proc. 2020;95(1):77–89. PMID:31630870 https://doi.org/10.1016/j.mayocp.2019.08.021

18. Ray KK, Troquay RPT, Visseren FLJ, Leiter LA, Wright RS, Vikarunnessa S, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11(2):109–119. PMID: 36620965 https://doi.org/10.1016/S2213-8587(22)00353-9

19. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Rall FJ, et al.; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–1519. PMID: 32187462 https://doi.org/10.1056/NEJ-Moa1912387

20. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis. 1991;18(3):353–358. PMID: 1882828 https://doi.org/10.1016/s0272-6386(12)80095-3

21. Lee AY, Jeong J, Heo K-N, Park S, Ah Y-M, Han JM, et al. Complications associated with immunosuppressive agents in solid organ transplant recipients: a nationwide analysis. J Clin Med. 2025;14(10):3602. PMID: 40429597 https://doi.org/10.3390/jcm14103602

22. Kucherov AA, Ershova AI, Syutkin VE, Drapkina OM. Features of lipid-lowering therapy in liver transplant recipients. Cardiovascular Therapy and Prevention. 2023;22(12):3872. (In Russ.). https://doi.org/10.15829/1728-8800-2023-3872